glp-1 and protein Smaller portions, more protein: How GLP-1s are quietly changing chain restaurant menus Pure Protein introduces all-in-one protein

Today, the term has become internet shorthand for experimenting with tiny doses of just about anything, including prescription medications

We have pharmacokinetic data that says, yes, it is being absorbed

Type 2 diabetes in adults: management (NG28) Initial medicines chapter

Engstrm et al., 2024)

Microdosing approaches On the opposite end of the spectrum, some researchers find success with microdosing tirzepatide or lower-dose protocols

ABSTRACT: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1 RAs are common therapies for managing diabetes and obesity, but gastrointestinal (GI) adverse effects (AEs) such as nausea, vomiting, diarrhea, and constipation frequently limit therapy